Profil
Paul Evans is the founder of Rosetta Partners LLC (Illinois), which was founded in 2006.
He held the title of Managing Partner in 2012.
Currently, Mr. Evans is the Chairman of Atterx Biotherapeutics, Inc. Additionally, he has worked as a Partner at Chicago Research & Trading Group Ltd.
Aktive Positionen von Paul Evans
| Unternehmen | Position | Beginn |
|---|---|---|
Atterx Biotherapeutics, Inc.
 Atterx Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Atterx Biotherapeutics, Inc. develops novel antibacterial technologies. It developed two products to fight multi-drug resistant, Gram negative bacteria. The first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections and GN-4474 has been developed using this technology to target Gram negative bacteria. It has been shown to be effective in animal infection models and an IND filing is expected in 2015. The company was founded by Richard R. Burgess and Marcin Filutowicz in 2001 and is headquartered in Madison, WI. | Vorsitzender | - |
Ehemalige bekannte Positionen von Paul Evans
| Unternehmen | Position | Ende |
|---|---|---|
Rosetta Partners LLC (Illinois)
 Rosetta Partners LLC (Illinois) Investment ManagersFinance Founded in 2006, Rosetta Partners LLC is a biotechnology investment group headquartered in Lake Forest, Illinois | Gründer | 11.05.2012 |
| Chicago Research & Trading Group Ltd. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Atterx Biotherapeutics, Inc.
Atterx Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Atterx Biotherapeutics, Inc. develops novel antibacterial technologies. It developed two products to fight multi-drug resistant, Gram negative bacteria. The first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections and GN-4474 has been developed using this technology to target Gram negative bacteria. It has been shown to be effective in animal infection models and an IND filing is expected in 2015. The company was founded by Richard R. Burgess and Marcin Filutowicz in 2001 and is headquartered in Madison, WI. | Health Technology |
| Chicago Research & Trading Group Ltd. | Finance |
Rosetta Partners LLC (Illinois)
Rosetta Partners LLC (Illinois) Investment ManagersFinance Founded in 2006, Rosetta Partners LLC is a biotechnology investment group headquartered in Lake Forest, Illinois | Finance |
